{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:54:29Z","timestamp":1790430869422,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-NR076986"],"award-info":[{"award-number":["RS-2023-NR076986"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00509114"],"award-info":[{"award-number":["RS-2024-00509114"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00400042"],"award-info":[{"award-number":["RS-2024-00400042"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00278980"],"award-info":[{"award-number":["RS-2023-00278980"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003693","name":"Korea Institute of Science and Technology","doi-asserted-by":"publisher","award":["2E33761"],"award-info":[{"award-number":["2E33761"]}],"id":[{"id":"10.13039\/501100003693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02623-6","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:50:55Z","timestamp":1775832655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rapid CAR screening and circRNA-driven CAR-NK cells for persistent shed-resistant immunotherapy"],"prefix":"10.1038","volume":"11","author":[{"given":"Joo-Yoon","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisu","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Min","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Won","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahye","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangwon","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7703-6421","authenticated-orcid":false,"given":"Seung-Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hun","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4552-4169","authenticated-orcid":false,"given":"Song Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-4423","authenticated-orcid":false,"given":"Chang-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2135-2983","authenticated-orcid":false,"given":"Mihue","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"2623_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier, E. et al. Innate or adaptive immunity? The example of natural killer cells. Science 331, 44\u201349 (2011).","journal-title":"Science"},{"key":"2623_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski, T. J., Biederstadt, A. & Rezvani, K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat. Rev. Cancer 22, 557\u2013575 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"2623_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41568-020-0272-z","volume":"20","author":"ND Huntington","year":"2020","unstructured":"Huntington, N. D., Cursons, J. & Rautela, J. The cancer-natural killer cell immunity cycle. Nat. Rev. Cancer 20, 437\u2013454 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"2623_CR4","first-page":"650","volume":"28","author":"J Moscarelli","year":"2022","unstructured":"Moscarelli, J., Zahavi, D., Maynard, R. & Weiner, L. M. The next generation of cellular immunotherapy: chimeric antigen receptor-natural killer cells. Transpl. Cell Ther. 28, 650\u2013656 (2022).","journal-title":"Transpl. Cell Ther."},{"key":"2623_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li, Y., Hermanson, D. L., Moriarity, B. S. & Kaufman, D. S. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell 23, 181\u2013192.e185 (2018).","journal-title":"Cell Stem Cell"},{"key":"2623_CR6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial. Nat. Med. 30, 772\u2013784 (2024).","journal-title":"Nat. Med."},{"key":"2623_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi, A. et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet 405, 127\u2013136 (2025).","journal-title":"Lancet"},{"key":"2623_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaci.2025.04.005","volume":"156","author":"MJ Lee","year":"2025","unstructured":"Lee, M. J., Cichocki, F. & Miller, J. S. CAR therapies: development, design, and implementation. J. Allergy Clin. Immunol. 156, 70\u201380 (2025).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2623_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coi.2018.03.013","volume":"51","author":"M Daher","year":"2018","unstructured":"Daher, M. & Rezvani, K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr. Opin. Immunol. 51, 146\u2013153 (2018).","journal-title":"Curr. Opin. Immunol."},{"key":"2623_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","volume":"15","author":"N Lamers-Kok","year":"2022","unstructured":"Lamers-Kok, N. et al. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. J. Hematol. Oncol. 15, 164 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2623_CR11","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","volume":"36","author":"S Srivastava","year":"2015","unstructured":"Srivastava, S. & Riddell, S. R. Engineering CAR-T cells: Design concepts. Trends Immunol. 36, 494\u2013502 (2015).","journal-title":"Trends Immunol."},{"key":"2623_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-00617-7","volume":"18","author":"D Liu","year":"2020","unstructured":"Liu, D. et al. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy. Cell Commun. Signal 18, 134 (2020).","journal-title":"Cell Commun. Signal"},{"key":"2623_CR13","doi-asserted-by":"crossref","unstructured":"Liao, Y. & Cairo, M. S. CAR-NK\u2019s balancing act: when scFv affinity is not too tight, not too loose but just right? J Immunother Cancer 13 (2025).","DOI":"10.1136\/jitc-2025-012139"},{"key":"2623_CR14","doi-asserted-by":"crossref","unstructured":"Rahnama, R. et al. Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality. J Immunother Cancer 13 (2025).","DOI":"10.1136\/jitc-2024-010763"},{"key":"2623_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02746-4","volume":"22","author":"EM McErlean","year":"2024","unstructured":"McErlean, E. M. & McCarthy, H. O. Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery. J. Nanobiotechnol. 22, 552 (2024).","journal-title":"J. Nanobiotechnol."},{"key":"2623_CR16","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","volume":"34","author":"R Hassan","year":"2016","unstructured":"Hassan, R. et al. Mesothelin Immunotherapy for Cancer: Ready for Prime Time? J. Clin. Oncol. 34, 4171\u20134179 (2016).","journal-title":"J. Clin. Oncol."},{"key":"2623_CR17","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3390\/cancers14061550","volume":"14","author":"JR Faust","year":"2022","unstructured":"Faust, J. R., Hamill, D., Kolb, E. A., Gopalakrishnapillai, A. & Barwe, S. P. Mesothelin: an immunotherapeutic target beyond solid tumors. Cancers 14, 1550 (2022).","journal-title":"Cancers"},{"key":"2623_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","volume":"6","author":"A Morello","year":"2016","unstructured":"Morello, A., Sadelain, M. & Adusumilli, P. S. Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Discov. 6, 133\u2013146 (2016).","journal-title":"Cancer Discov."},{"key":"2623_CR19","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","volume":"20","author":"SS Kachala","year":"2014","unstructured":"Kachala, S. S. et al. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin. Cancer Res. 20, 1020\u20131028 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2623_CR20","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/s41417-024-00816-1","volume":"31","author":"M Malla","year":"2024","unstructured":"Malla, M. et al. Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer. Cancer Gene Ther. 31, 1547\u20131558 (2024).","journal-title":"Cancer Gene Ther."},{"key":"2623_CR21","doi-asserted-by":"publisher","first-page":"e006130","DOI":"10.1136\/jitc-2022-006130","volume":"11","author":"YE Lee","year":"2023","unstructured":"Lee, Y. E. et al. Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6. J. Immunother. Cancer 11, e006130 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"2623_CR22","doi-asserted-by":"publisher","first-page":"5718","DOI":"10.1158\/1078-0432.CCR-21-1546","volume":"27","author":"Q Le","year":"2021","unstructured":"Le, Q. et al. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. Clin. Cancer Res. 27, 5718\u20135730 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2623_CR23","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1158\/1535-7163.MCT-15-0863","volume":"15","author":"P Awuah","year":"2016","unstructured":"Awuah, P., Bera, T. K., Folivi, M., Chertov, O. & Pastan, I. Reduced shedding of surface mesothelin improves efficacy of Mesothelin-targeting recombinant immunotoxins. Mol. Cancer Ther. 15, 1648\u20131655 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"2623_CR24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-23-0233","volume":"23","author":"A Chakraborty","year":"2024","unstructured":"Chakraborty, A. et al. A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin. Mol. Cancer Ther. 23, 1021\u20131030 (2024).","journal-title":"Mol. Cancer Ther."},{"key":"2623_CR25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202439119","volume":"119","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. Proc. Natl. Acad. Sci. USA 119, e2202439119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2623_CR26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2317283121","volume":"121","author":"XF Liu","year":"2024","unstructured":"Liu, X. F. et al. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope. Proc. Natl. Acad. Sci. USA 121, e2317283121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2623_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1158\/1535-7163.MCT-11-0454","volume":"11","author":"RJ Kelly","year":"2012","unstructured":"Kelly, R. J., Sharon, E., Pastan, I. & Hassan, R. Mesothelin-targeted agents in clinical trials and in preclinical development. Mol. Cancer Ther. 11, 517\u2013525 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"2623_CR28","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1158\/1535-7163.MCT-22-0073","volume":"21","author":"S Tomar","year":"2022","unstructured":"Tomar, S. et al. Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors. Mol. Cancer Ther. 21, 1195\u20131206 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"2623_CR29","doi-asserted-by":"crossref","unstructured":"Chakraborty, A. et al. A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin. Mol Cancer Ther. OF1-OF10 (2024).","DOI":"10.1158\/1535-7163.26145078"},{"key":"2623_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl3995","volume":"7","author":"Q Xiao","year":"2022","unstructured":"Xiao, Q. et al. Size-dependent activation of CAR-T cells. Sci. Immunol. 7, eabl3995 (2022).","journal-title":"Sci. Immunol."},{"key":"2623_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1711-1","volume":"10","author":"Z Zhang","year":"2019","unstructured":"Zhang, Z. et al. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor. Cell Death Dis. 10, 476 (2019).","journal-title":"Cell Death Dis."},{"key":"2623_CR32","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-025-02332-6","volume":"10","author":"Z Chao","year":"2025","unstructured":"Chao, Z. et al. Immunological synapse: structures, molecular mechanisms and therapeutic implications in disease. Signal Transduct. Target Ther. 10, 254 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"2623_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"2623_CR34","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41375-022-01585-2","volume":"36","author":"ML Olson","year":"2022","unstructured":"Olson, M. L. et al. Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion. Leukemia 36, 1943\u20131946 (2022).","journal-title":"Leukemia"},{"key":"2623_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04041-6","volume":"21","author":"P Celichowski","year":"2023","unstructured":"Celichowski, P. et al. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility. J. Transl. Med. 21, 197 (2023).","journal-title":"J. Transl. Med."},{"key":"2623_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00417-w","volume":"10","author":"M Mazinani","year":"2022","unstructured":"Mazinani, M. & Rahbarizadeh, F. CAR-T cell potency: from structural elements to vector backbone components. Biomark. Res. 10, 70 (2022).","journal-title":"Biomark. Res."},{"key":"2623_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add6997","volume":"9","author":"L Li","year":"2023","unstructured":"Li, L. et al. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci. Adv. 9, eadd6997 (2023).","journal-title":"Sci. Adv."},{"key":"2623_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3389\/fimmu.2020.00311","volume":"11","author":"S Regis","year":"2020","unstructured":"Regis, S., Dondero, A., Caliendo, F., Bottino, C. & Castriconi, R. N. K. Cell Function Regulation by TGF-beta-Induced Epigenetic Mechanisms. Front Immunol. 11, 311 (2020).","journal-title":"Front Immunol."},{"key":"2623_CR39","doi-asserted-by":"publisher","first-page":"e142116","DOI":"10.1172\/JCI142116","volume":"131","author":"H Shaim","year":"2021","unstructured":"Shaim, H. et al. Targeting the alphav integrin\/TGF-beta axis improves natural killer cell function against glioblastoma stem cells. J. Clin. Invest 131, e142116 (2021).","journal-title":"J. Clin. Invest"},{"key":"2623_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41416-019-0479-5","volume":"121","author":"E Karamitopoulou","year":"2019","unstructured":"Karamitopoulou, E. Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Br. J. Cancer 121, 5\u201314 (2019).","journal-title":"Br. J. Cancer"},{"key":"2623_CR41","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/cas.16418","volume":"116","author":"Z Wang","year":"2025","unstructured":"Wang, Z. et al. Cancer-associated fibroblast-derived MMP11 promotes tumor progression in pancreatic cancer. Cancer Sci. 116, 643\u2013655 (2025).","journal-title":"Cancer Sci."},{"key":"2623_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/978-1-0716-2285-8_17","volume":"2491","author":"DS Baek","year":"2022","unstructured":"Baek, D. S., Park, S. W., Adams, C., Dimitrov, D. S. & Kim, Y. S. Yeast Mating as a Tool for Highly Effective Discovery and Engineering of Antibodies via Display Methodologies. Methods Mol. Biol. 2491, 313\u2013333 (2022).","journal-title":"Methods Mol. Biol."},{"key":"2623_CR43","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4014\/jmb.1401.01002","volume":"24","author":"DS Baek","year":"2014","unstructured":"Baek, D. S. & Kim, Y. S. Construction of a large synthetic human Fab antibody library on yeast cell surface by optimized yeast mating. J. Microbiol Biotechnol. 24, 408\u2013420 (2014).","journal-title":"J. Microbiol Biotechnol."},{"key":"2623_CR44","first-page":"5151","volume":"32","author":"J Zhang","year":"2012","unstructured":"Zhang, J. et al. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. Anticancer Res 32, 5151\u20135158 (2012).","journal-title":"Anticancer Res"},{"key":"2623_CR45","doi-asserted-by":"publisher","first-page":"17099","DOI":"10.1073\/pnas.0708101104","volume":"104","author":"Y Zhang","year":"2007","unstructured":"Zhang, Y., Xiang, L., Hassan, R. & Pastan, I. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc. Natl. Acad. Sci. USA 104, 17099\u201317104 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2623_CR46","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.3770","volume":"18","author":"CH Lee","year":"2017","unstructured":"Lee, C. H. et al. IgG Fc domains that bind C1q but not effector Fcgamma receptors delineate the importance of complement-mediated effector functions. Nat. Immunol. 18, 889\u2013898 (2017).","journal-title":"Nat. Immunol."},{"key":"2623_CR47","doi-asserted-by":"publisher","first-page":"457","DOI":"10.4196\/kjpp.2024.28.5.457","volume":"28","author":"M Kim","year":"2024","unstructured":"Kim, M. et al. Construction and validation of a synthetic phage-displayed nanobody library. Korean J. Physiol. Pharm. 28, 457\u2013467 (2024).","journal-title":"Korean J. Physiol. Pharm."},{"key":"2623_CR48","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh, M. et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568, 112\u2013116 (2019).","journal-title":"Nature"},{"key":"2623_CR49","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","volume":"28","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat. Med. 28, 2133\u20132144 (2022).","journal-title":"Nat. Med."},{"key":"2623_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01952-w","volume":"23","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects. Mol. Cancer 23, 56 (2024).","journal-title":"Mol. Cancer"},{"key":"2623_CR51","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng, L., Sferruzza, G., Yang, L., Zhou, L. & Chen, S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol. Immunol. 21, 1089\u20131108 (2024).","journal-title":"Cell Mol. Immunol."},{"key":"2623_CR52","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","volume":"6","author":"K Shah","year":"2021","unstructured":"Shah, K., Al-Haidari, A., Sun, J. & Kazi, J. U. T cell receptor (TCR) signaling in health and disease. Signal Transduct. Target Ther. 6, 412 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2623_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106656","volume":"188","author":"Y Peng","year":"2023","unstructured":"Peng, Y. et al. Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma. Pharm. Res. 188, 106656 (2023).","journal-title":"Pharm. Res."},{"key":"2623_CR54","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.clim.2015.08.005","volume":"161","author":"AC Issekutz","year":"2015","unstructured":"Issekutz, A. C., Derfalvi, B., Kasermann, F. & Rowter, D. Potentiation of cytokine-induced proliferation of human Natural Killer cells by intravenous immunoglobulin G. Clin. Immunol. 161, 373\u2013383 (2015).","journal-title":"Clin. Immunol."},{"key":"2623_CR55","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.ccell.2024.07.007","volume":"42","author":"M Shanley","year":"2024","unstructured":"Shanley, M. et al. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer Cell 42, 1450\u20131466.e1411 (2024).","journal-title":"Cancer Cell"},{"key":"2623_CR56","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nri3044","volume":"11","author":"JC Sun","year":"2011","unstructured":"Sun, J. C. & Lanier, L. L. NK cell development, homeostasis and function: parallels with CD8(+) T cells. Nat. Rev. Immunol. 11, 645\u2013657 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"2623_CR57","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1261\/rna.047126.114","volume":"20","author":"E Lasda","year":"2014","unstructured":"Lasda, E. & Parker, R. Circular RNAs: diversity of form and function. RNA 20, 1829\u20131842 (2014).","journal-title":"RNA"},{"key":"2623_CR58","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.molcel.2019.02.015","volume":"74","author":"RA Wesselhoeft","year":"2019","unstructured":"Wesselhoeft, R. A. et al. RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration In Vivo. Mol. Cell 74, 508\u2013520.e504 (2019).","journal-title":"Mol. Cell"},{"key":"2623_CR59","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41587-022-01393-0","volume":"41","author":"R Chen","year":"2023","unstructured":"Chen, R. et al. Engineering circular RNA for enhanced protein production. Nat. Biotechnol. 41, 262\u2013272 (2023).","journal-title":"Nat. Biotechnol."},{"key":"2623_CR60","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ccell.2022.04.011","volume":"40","author":"H Huang","year":"2022","unstructured":"Huang, H. et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell 40, 656\u2013673.e657 (2022).","journal-title":"Cancer Cell"},{"key":"2623_CR61","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.tibtech.2023.08.005","volume":"42","author":"J Wu","year":"2024","unstructured":"Wu, J., Wu, W., Zhou, B. & Li, B. Chimeric antigen receptor therapy meets mRNA technology. Trends Biotechnol. 42, 228\u2013240 (2024).","journal-title":"Trends Biotechnol."},{"key":"2623_CR62","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3390\/cancers15051357","volume":"15","author":"X Zhai","year":"2023","unstructured":"Zhai, X., Mao, L., Wu, M., Liu, J. & Yu, S. Challenges of Anti-Mesothelin CAR-T-Cell Therapy. Cancers 15, 1357 (2023).","journal-title":"Cancers"},{"key":"2623_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11806-1","volume":"24","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer. BMC Cancer 24, 119 (2024).","journal-title":"BMC Cancer"},{"key":"2623_CR64","doi-asserted-by":"publisher","first-page":"e162530","DOI":"10.1172\/JCI162530","volume":"133","author":"P Wong","year":"2023","unstructured":"Wong, P. et al. T-BET and EOMES sustain mature human NK cell identity and antitumor function. J. Clin. Invest. 133, e162530 (2023).","journal-title":"J. Clin. Invest."},{"key":"2623_CR65","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s12276-024-01220-3","volume":"56","author":"HJ Hwang","year":"2024","unstructured":"Hwang, H. J. & Kim, Y. K. Molecular mechanisms of circular RNA translation. Exp. Mol. Med. 56, 1272\u20131280 (2024).","journal-title":"Exp. Mol. Med."},{"key":"2623_CR66","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","volume":"348","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. J. Control Release 348, 84\u201394 (2022).","journal-title":"J. Control Release"},{"key":"2623_CR67","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/334320a0","volume":"334","author":"J Pelletier","year":"1988","unstructured":"Pelletier, J. & Sonenberg, N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 334, 320\u2013325 (1988).","journal-title":"Nature"},{"key":"2623_CR68","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41551-024-01245-z","volume":"9","author":"M Tong","year":"2025","unstructured":"Tong, M. et al. Robust genome and cell engineering via in vitro and in situ circularized RNAs. Nat. Biomed. Eng. 9, 109\u2013126 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"2623_CR69","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1016\/j.ymthe.2024.11.035","volume":"33","author":"YR Li","year":"2024","unstructured":"Li, Y. R. et al. Managing allorejection in off-the-shelf CAR-engineered cell therapies. Mol. Ther. 33, 2368\u20132390 (2024).","journal-title":"Mol. Ther."},{"key":"2623_CR70","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/s12276-024-01251-w","volume":"56","author":"SW Choi","year":"2024","unstructured":"Choi, S. W. & Nam, J. W. Optimal design of synthetic circular RNAs. Exp. Mol. Med 56, 1281\u20131292 (2024).","journal-title":"Exp. Mol. Med"},{"key":"2623_CR71","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/s41551-024-01306-3","volume":"9","author":"Y Du","year":"2024","unstructured":"Du, Y. et al. Efficient circular RNA synthesis for potent rolling circle translation. Nat. Biomed. Eng. 9, 1062\u20131074 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"2623_CR72","doi-asserted-by":"publisher","first-page":"2315655","DOI":"10.1080\/15384047.2024.2315655","volume":"25","author":"DS Lefler","year":"2024","unstructured":"Lefler, D. S., Manobianco, S. A. & Bashir, B. Immunotherapy resistance in solid tumors: mechanisms and potential solutions. Cancer Biol. Ther. 25, 2315655 (2024).","journal-title":"Cancer Biol. Ther."},{"key":"2623_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.786728","volume":"9","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. TGF-beta Signaling and Resistance to Cancer Therapy. Front Cell Dev. Biol. 9, 786728 (2021).","journal-title":"Front Cell Dev. Biol."},{"key":"2623_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07544-w","volume":"16","author":"Y Pan","year":"2025","unstructured":"Pan, Y. et al. Regulatory T cells in solid tumor immunotherapy: effect, mechanism and clinical application. Cell Death Dis. 16, 277 (2025).","journal-title":"Cell Death Dis."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02623-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02623-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02623-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T16:02:40Z","timestamp":1775836960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02623-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2623"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02623-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.08.19.671003","asserted-by":"object"}]},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C-H.L. and J.S.H. (KR10-2024-0059322) and M.J., C.-H.L., J.Y.J., and J.S.H. are listed as inventors on provisional patents (KR10-2025-0013774). The authors declare that they have no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}